Affimed (AFMD) Stock: Gaining Big On Clinical Data

Affimed N.V. AFMD Stock News

Affimed N.V. (NASDAQ: AFMD) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced clinical data from two separate trials, leading to excitement among investors and sending the stock for the top. Today, we’ll talk about the data, what we’re seeing from the stock, and what we’ll be watching for with regard to AFMD ahead.

AFMD Releases Clinical Data 

As mentioned above, Affimed is having an incredibly strong day in the market today after issuing a press release surrounding key clinical data. In the release, the company reported additional preliminary patient data from two separate clinical studies surrounding its leading candidate. That candidate is AFM13, a NK cell engager candidate.




In the release, AFMD said that the data demonstrate that AFM12 was well-tolerated and showed promising therapeutic efficacy. This was the case in both, a combination study with the anti-PD-1 antibody Keytruda(R) in Hodgkin lymphoma and as a monotherapy in CD30-positive lymphoma. In a statement, Dr. Adi Hoess, CEO at AFMD, had the following to offer:

We are extremely encouraged by these new data which indicate that the first-in-class NK cell engager AFM13 has achieved clinically meaningful responses both as single agent and in combination with a checkpoint inhibitor… In particular, in our combination trial with Keytruda, we are excited to have increased both overall and complete metabolic response rates.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Leave a Comment